Valaciclovir
Overactive Bladder Syndrome
Buddhist Tzu Chi General HospitalSmall moleculePhase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the Overactive Bladder Syndrome cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Oxybutynin Transdermal Patch University of California, Davis | Phase 3 | B |
Mitoquinol mesilate Iman Al-Naggar, PhD | Phase 2 | CCC |
Same molecule, other indications
Valaciclovir is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →